A phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic BRAF-mutant colorectal cancer

Robin M.J.M. Van Geel, Josep Tabernero, Elena Elez, Johanna C. Bendell, Anna Spreafico, Martin Schuler, Takayuki Yoshino, Jean Pierre Delord, Yasuhide Yamada, Martijn P. Lolkema, Jason E. Faris, Ferry A.L.M. Eskens, Sunil Sharma, Rona Yaeger, Heinz Josef Lenz, Zev A. Wainberg, Emin Avsar, Arkendu Chatterjee, Savina Jaeger, Eugene TanKati Maharry, Tim Demuth, Jan H.M. Schellens

Research output: Contribution to journalArticleResearchpeer-review

127 Citations (Scopus)

Fingerprint

Dive into the research topics of 'A phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic BRAF-mutant colorectal cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences